WO2009088805A2 - Antibody targeting through a modular recognition domain - Google Patents
Antibody targeting through a modular recognition domain Download PDFInfo
- Publication number
- WO2009088805A2 WO2009088805A2 PCT/US2008/088337 US2008088337W WO2009088805A2 WO 2009088805 A2 WO2009088805 A2 WO 2009088805A2 US 2008088337 W US2008088337 W US 2008088337W WO 2009088805 A2 WO2009088805 A2 WO 2009088805A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- mrd
- sequence
- targeting
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title claims description 91
- 238000000034 method Methods 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 140
- 230000027455 binding Effects 0.000 claims description 92
- 108010044426 integrins Proteins 0.000 claims description 58
- 102000006495 integrins Human genes 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 102000001301 EGF receptor Human genes 0.000 claims description 25
- 108060006698 EGF receptor Proteins 0.000 claims description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 25
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 25
- 230000002491 angiogenic effect Effects 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 25
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 24
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000033115 angiogenesis Effects 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 238000002823 phage display Methods 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 7
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 5
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 5
- 229940053128 nerve growth factor Drugs 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 description 82
- 239000000203 mixture Substances 0.000 description 30
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 23
- 230000003197 catalytic effect Effects 0.000 description 22
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 21
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 102100034608 Angiopoietin-2 Human genes 0.000 description 20
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 20
- 208000026310 Breast neoplasm Diseases 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 229940022353 herceptin Drugs 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- -1 Ang-2 Proteins 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940082789 erbitux Drugs 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 description 4
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
- 102000004264 Osteopontin Human genes 0.000 description 3
- 108010081689 Osteopontin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000001023 pro-angiogenic effect Effects 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000006668 aldol addition reaction Methods 0.000 description 2
- 238000005575 aldol reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000054366 human GPA33 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- HLOFWGGVFLUZMZ-UHFFFAOYSA-N 4-hydroxy-4-(6-methoxynaphthalen-2-yl)butan-2-one Chemical compound C1=C(C(O)CC(C)=O)C=CC2=CC(OC)=CC=C21 HLOFWGGVFLUZMZ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102100033402 Angiopoietin-4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100216078 Mus musculus Ang4 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000006481 angiogenic pathway Effects 0.000 description 1
- 108010069801 angiopoietin 4 Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000032147 negative regulation of DNA repair Effects 0.000 description 1
- 230000023837 negative regulation of proteolysis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000016359 neuroblastic tumor Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- This invention relates generally to antibodies containing one or more modular recognition domains and more specifically to the use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains.
- Catalytically active monoclonal antibodies can be used for selective prodrug activation and chemical transformations.
- Monoclonal Abs with aldolase activity have emerged as highly efficient catalysts for a number of chemical transformations, particularly aldol and retro-aldol reactions.
- the retro-aldolase activity of Abs, such as 38C2 and 93F3 have allowed researchers to design, synthesize, and evaluate prodrugs of various chemotherapeutic agents that can be activated by retro-aldol reactions. (Construction of 38C2 was described in WO 97/21803, herein incorporated by reference).
- 38C2 contains an antibody combining site that catalyzes the aldol addition reaction between an aliphatic donor and an aldehyde acceptor.
- 38C2 In a syngeneic mouse model of neuroblastoma, systemic administration of an etoposide prodrug and intra-tumor injection of 38C2 inhibited tumor growth.
- catalytic Abs lack a device to target the catalytic Ab to the malignant cells.
- ADPT antibody-directed enzyme prodrug therapy
- ADAPT antibody-directed abzyme prodrug therapy
- catalytic antibodies can be directed to tumor cells by chemical conjugation or recombinant fusion to targeting antibodies.
- a more efficient alternative would be using the catalytic antibody fused to a targeting peptide located outside the antibody combining site, thereby leaving the active site available for the prodrug activation.
- bispecific antibodies have been prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma.
- Dual- specific, tetravalent IgG-like molecules, or dual-variable-domain immunoglobins have been engineered from two monoclonal antibodies. Thes dual-variable-domain immunoglobins are capable of binding both antigens in the presence of serum.
- these approaches present challenges with respect to manufacturing, yield and purity.
- BsAb fragments such as diabody, minibody, and Fab-scFv fusion proteins.
- BsAb fragments may possess some advantages over the full-length IgG-like molecules for certain clinical applications, such as for tumor radio-imaging and targeting, because of better tissue penetration and faster clearance from the circulation.
- IgG-like BsAb may prove to be preferred over smaller BsAb fragments for other in vivo applications, specifically for oncology indications, by providing the Fc domain that confers long serum half-life and supports secondary immune function, such as antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity.
- Peptibodies are essentially peptide fusions with antibody Fc regions. Given the success of studies using random peptide libraries to find high-affinity peptide ligands for a wide variety of targets, fusion of such peptides to antibody Fc regions provides a means of making peptides into therapeutic candidates by increasing their circulatory half-life and activity through increased valency.
- Protein interactions with other molecules is basic to biochemistry. Protein interactions include receptor-ligand interactions, antibody-antigen interactions, cell-cell contact and pathogen interactions with target tissues. Protein interactions can involve contact with other proteins, with carbohydrates, oligosaccharides, lipids, metal ions and the like materials.
- the basic unit of protein interaction is the region of the protein involved in contact and recognition, and is referred to as the binding site or target site.
- Peptides derived from phage display libraries typically retain their binding characteristics when linked to other molecules.
- Specific peptides of this type can be treated as modular specificity blocks or molecular recognition domains (MPvDs) that can be combined to create a single protein with binding specificities for several defined targets.
- MPvDs molecular recognition domains
- Integrins are a family of transmembrane cell adhesion receptors that are composed of ⁇ and ⁇ subunits and mediate cell attachment to proteins within the extracellular matrix. At present, eighteen ⁇ and eight ⁇ subunits are known; these form 24 different ⁇ heterodimers with different specificities for various ECM cell-adhesive proteins. Ligands for various integrins include fibronectin, collagen, laminin, von Willebrand factor, osteopontin, thrombospondin, and vitronectin, which are all components of the ECM.
- Integrins can also bind to soluble ligands such as fibrinogen or to other adhesion molecules on adjacent cells. Integrins are known to exist in distinct activation states that exhibit different affinities for ligand. Recognition of soluble ligands by integrins strictly depends on specific changes in receptor conformation. This provides a molecular switch that controls the ability of cells to aggregate in an integrin dependent manner and to arrest under the dynamic flow conditions of the vasculature. This mechanism is well established for leukocytes and platelets that circulate within the blood stream in a resting state while expressing non-activated integrins.
- the activated receptor strongly promotes cancer cell migration and enables the cells to arrest under blood flow conditions, hi this way, activation of ⁇ v ⁇ 3 endows metastatic cells with key properties likely to be critical for successful dissemination and colonization of target organs.
- Tumor cells that have successfully entered a target organ may further utilize ⁇ v ⁇ 3 to thrive in the new environment, as ⁇ v ⁇ 3 matrix interactions can promote cell survival and proliferation.
- ⁇ v ⁇ 3 binding to osteopontin promotes malignancy and elevated levels of osteopontin correlate with a poor prognosis in breast cancer.
- the ⁇ v ⁇ 3 integrin is one of the most widely studied integrins. Antagonists of this molecule have significant potential for use in targeted drug delivery.
- One approach that has been used to target ⁇ v ⁇ 3 integrin uses the high binding specificity to ⁇ v ⁇ 3 of peptides containing the Arg-Gly-Asp (RGD) sequence. This tripeptide, naturally present in extracellular matrix proteins, is the primary binding site of the ⁇ v ⁇ 3 integrin.
- RGD based reporter probes are problematic due to fast blood clearance, high kidney and liver uptake and fast tumor washout. Chemical modification of cyclised RGD peptides has been shown to increase their stability and valency. These modified peptides are then coupled to radio-isotpes and used either for tumor imaging or to inhibit tumor growth.
- Integrin ⁇ v ⁇ 3 is one of the most well characterized integrin heterodimers and is one of several heterodimers that have been implicated in tumor-induced angiogenesis. While sparingly expressed in mature blood vessels, ⁇ v ⁇ 3 is significantly up-regulated during angiogenesis in vivo. The expression of ⁇ v ⁇ 3 correlates with aggressiveness of disease in breast and cervical cancer as well as in malignant melanoma. Recent studies suggest that ⁇ v ⁇ 3 may be useful as a diagnostic or prognostic indicator for some tumors. Integrin ⁇ v ⁇ 3 is particularly attractive as a therapeutic target due to its relatively limited cellular distribution. It is not generally expressed on epithelial cells, and minimally expressed on other cell types. Furthermore, ⁇ v ⁇ 3 antagonists, including both cyclic RGD peptides and monoclonal antibodies, significantly inhibit cytokine-induced angiogenesis and the growth of solid tumor on the chick chorioallantoic membrane.
- ⁇ v ⁇ 5 Another integrin heterodimer, ⁇ v ⁇ 5, is more widely expressed on malignant tumor cells and is likely involved in VEGF-mediated angiogenesis. It has been shown that ⁇ v ⁇ 3 and ⁇ v ⁇ 5 promote angiogenesis via distinct pathways: ⁇ v ⁇ 3 through bFGF and TNF-a, and ⁇ v ⁇ 5 through VEGF and TGF- ⁇ . It has also been shown that inhibition of Src kinase can block VEGF-induced, but not FGF2-induced, angiogenesis. These results strongly imply that FGF2 and VEGF activate different angiogenic pathways that require ⁇ v ⁇ 3 and ⁇ v ⁇ 5, respectively.
- Integrins have also been implicated in tumor metastasis. Metastasis is the primary cause of morbidity and mortality in cancer. Malignant progression of melanoma, glioma, ovarian, and breast cancer have all been strongly linked with the expression of the integrin ⁇ v ⁇ 3 and in some cases with ⁇ v ⁇ 5. More recently, it has been shown that activation of integrin ⁇ v ⁇ 3 plays a significant role in metastasis in human breast cancer. A very strong correlation between expression of ⁇ v ⁇ 3 and breast cancer metastasis has been noted where normal breast epithelia are ⁇ v ⁇ 3 negative and approximately 50% of invasive lobular carcinomas and nearly all bone metastases in breast cancer express ⁇ v ⁇ 3. Antagonism of ⁇ v ⁇ 3 with a cyclic peptide has been shown to synergize with radioimmunotherapy in studies involving breast cancer xenografts.
- Angiogenesis the formation of new blood vessels from existing ones, is essential to may physiological and pathological processes. Normally, angiogenesis is tightly regulated by pro- and anti-angiogenic factors, but in the case of diseases such as cancer, ocular neovascular disease, arthritis and psoriasis, the process can go awry.
- diseases such as cancer, ocular neovascular disease, arthritis and psoriasis
- the association of angiogenesis with disease has made the discovery of anti-angiogenic compound attractive.
- Tie-2 is a receptor tyrosine kinase with four known ligands, angiopoietin-1 (Angl) through angiopoietin-4 (Ang4), the best studied being Angl and Ang2.
- Angl stimulates phosphorylation of Tie2 and the Ang2 interaction with Tie2 has been shown to both antagonize and agonize Tie2 receptor phosphorylation. Elevated Ang2 expression at sites of normal and pathological postnatal angiogenesis circumstantially implies a proangiogenic role for Ang2. Vessel-selective Ang2 induction associated with angiogenesis has been demonstrated in diseases including cancer. In patients with colon carcinoma, Ang2 is expressed ubiquitously in tumor epithelium, whereas expression of Angl in tumor epithelium was shown to be rare. The net gain of Ang2 activity has been suggested to be an initiating factor for tumor angiogenesis.
- Herceptin (Trastuzumab), developed by Genentech, is a recombinant humanized monoclonal antibody directed against the extracellular domain of the human epidermal tyrosine kinase receptor 2 (HER2 or ErbB2).
- HER2 human epidermal tyrosine kinase receptor 2
- the HER2 gene is overexpressed in 25% of invasive breast cancers, and is associated with poor prognosis and altered sensitivity to chemotherapeutic agents.
- Herceptin blocks the proliferation of ErbB2-overexpressing breast cancers, and is currently the only ErbB2 targeted antibody therapy approved by the FDA for the treatment of ErbB2 over-expressing metastatic breast cancer (MBC).
- ErbB2 In normal adult cells, few ErbB2 molecules exist at the cell surface ⁇ 20,000 per cell, so few heterodimers are formed and growth signals are relatively weak and controllable. When ErbB2 is overexpressed, ⁇ 500,000 per cell, multiple ErbB2 heterodimers are formed and cell signaling is stronger, resulting in enhanced responsiveness to growth factors and malignant growth. This explains why ErbB2 overexpression is an indicator of poor prognosis in breast tumors and may be predictive of response to treatment.
- ErbB2 is a promising and validated target for breast cancer, where it is found both in primary tumor and metastatic sites.
- Herceptin induces rapid removal of ErbB2 from the cell surface, thereby reducing its availability to heterodimerize and promote growth.
- Mechanisms of action of Herceptin observed in experimental in vitro and in vivo models include inhibition of proteolysis of ErbB2's extracellular domain, disruption of downstream signaling pathways such as phosphatidylinositiol 3-kinase (P 13K) and mitogen-activated protein kinase (MAPK) cascades, GI cell-cycle arrest, inhibition of DNA repair, suppression of angiogenesis and induction of antibody dependent cellular cytotoxicity (ADCC).
- P 13K phosphatidylinositiol 3-kinase
- MAK mitogen-activated protein kinase
- ADCC antibody dependent cellular cytotoxicity
- IGF-IR insulin-like growth factor- 1 receptor
- IGF-IR is a receptor-tyrosine kinase that plays a critical role in signaling cell survival and proliferation.
- the IGF system is frequently deregulated in cancer cells by the establishment of autocrine loops involving IGF-I or -II and/or IGF-IR overexpression.
- epidemiological studies have suggested a link between elevated IGF levels and the development of major human cancers, such as breast, colon, lung and prostate cancer. Expression of IGFs and their cognate receptors has been correlated with disease stage, reduced survival, development of metastases and tumor de-differentiation.
- epidermal growth factor receptor EGFR
- EGFR epidermal growth factor receptor
- IGF-IR insulin growth factor-IR
- overexpression and/or activation of IGF-IR in tumor cells might contribute to their resistance to chemotherapeutic agents, radiation, or antibody therapy such as Herceptin. And consequently, inhibition of IGF-IR signaling has resulted in increased sensitivity of tumor cells to Herceptin.
- EGFR is a receptor tyrosine kinase that is expressed on many normal tissues as well as neoplastic lesions of most organs. Overexpression of EGFR or expression of mutant forms of EGFR has been observed in many tumors, particularly epithelial tumors, and is associated with poor clinical prognosis. Inhibition of signaling through this receptor induces an anti-tumor effect.
- Cetuximab also known as Erbitux (a mouse/human chimeric antibody) in February of 2004, EGFR became an approved antibody drug target for the treatment of metastatic colorectal cancer.
- Erbitux also received FDA approval for the treatment squamous cell carcinoma of the head and neck (SCCHN).
- Vectibix a fully human antibody directed against EGFR, was approved for metastatic colorectal cancer. Neither drug is a stand-alone agent in colorectal cancer - they were approved as add-ons to existing colorectal regimens.
- Erbitux is given in combination with the drug irinotecan and Vectibix is administered after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. Erbitux has been approved as a single agent in recurrent or metastatic SCCHN only where prior platinum-based chemotherapy has failed. Advanced clinical trials which use these drugs to target non-small cell lung carcinoma are ongoing.
- MRDs modular recognition domains
- MRDs can be appended on any of the termini of either heavy or light chains of a typical antibody.
- the first schematic represents a simple peptibody with a peptide fused to the C-terminus of an Fc. This approach provided for the preparation of bi-, tri-, tetra, and penta-specific antibodies. Display of a single MRD at each N- and C-termini of an IgG provides for octavalent display of the MRD.
- high-affinity peptides selected from phage display libraries or derived from natural ligands may offer a highly versatile and modular approach to the construction of multifunctional antibodies that retain both the binding and half-life advantages of traditional antibodies.
- MRDs can also extend the binding capacity of non-catalytic antibodies, providing for an effective approach to extend the binding functionality of antibodies, particularly for therapeutic purposes.
- the present invention is directed towards a full length antibody comprising a modular recognition domain (MRD). Also embodied in the present invention are variants and derivitaves of such antibodies comprising a MRD.
- MRD modular recognition domain
- the antibody and the MRD are operably linked through a linker peptide.
- the linker peptide is between 2 to 20 peptides long, or between 4 to 10 or about 4 to 15 peptides long.
- the linker peptide comprises the sequence GGGS (SEQ ID. NO.:1), the sequence SSGGGGSGGGGGGSS (SEQ ID. NO.: 2), or the sequence SSGGGGSGGGGGGSSRSS (SEQ ID NO.: 19).
- Other linkers containing a core sequence GGGS as shown in SEQ ID NO:1 are included herein wherein the linker peptide is from about 4-20 amino acids.
- the MRD is operably linked to the C-terminal end of the heavy chain of the antibody.
- the MRD is operably linked to the N-terminal end of the heavy chain of the antibody, hi yet another aspect, the MRD is operably linked to the C-terminal end of the light chain of the antibody.
- the MRD is operably linked to the N-terminal end of the light chain of the antibody.
- two or more MRDs are operably linked to any terminal end of the antibody.
- two or more MRDs are operably linked to two or more terminal ends of the antibody.
- the target of the MRD is a cellular antigen. In one embodiment of the present invention, the target of the MRD is CD20.
- the target of the MRD is an integrin.
- the peptide sequence of the integrin targeting MRD is YCRGDCT (SEQ ID. NO.:3).
- the peptide sequence of the integrin targeting MRD is PCRGDCL (SEQ ID. NO.:4).
- the peptide sequence of the integrin targeting MRD is TCRGDCY (SEQ ID. NO.:5).
- the peptide sequence of the integrin targeting MRD is LCRGDCF (SEQ ID. NO.:6).
- the target of the MRD is an angiogenic cytokine.
- the peptide sequence of the angiogenic cytokine targeting MRD is MGAQTNFMPMDDLEQRLYEQFILQQGLE (SEQ ID. NO.:7). In another aspect, the peptide sequence of the angiogenic cytokine targeting MRD is MGAQTNFMPMDNDELLLYEQFILQQGLE (SEQ ID. NO.: 8). In yet another aspect, the peptide sequence of the angiogenic cytokine targeting MRD is
- MGAQTNFMPMDATETRLYEQFILQQGLE SEQ ID. NO.:9.
- the peptide sequence of the angiogenic cytokine targeting MRD is
- the peptide sequence of the angiogenic cytokine targeting MRD is MGAQTNFMPMDNDELLNYEQFILQQGLE (SEQ ID. NO.: 11).
- the peptide sequence of the angiogenic cytokine targeting MRD is PXDNDXLLNY (SEQ ID. NO.: 12), where X is one of the 20 naturally-occurring amino acids.
- the targeting MRD peptide has the core sequence MGAQTNFMPMDXn (SEQ ID NO:56), wherein X is any amino acid and n is from about 0 to 15.
- the targeting MRD peptide contains a core sequence selected from:
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 22);
- nELAPWTXn where n is from about 0 to 50 amino acid residues (SEQ ID NO: 25);
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 28);
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 31);
- n is from about 0 to 50 amino acid residues and X, X 1 and X 2 are any amino acid (SEQ ID NO:57).
- Exemplary peptides containing such core peptides include for example:
- AQQEECEFAPWTCEHM (SEQ ID NO:21); AQQEECEFAPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEFAPWTCEHMLE (SEQ ID NO: 23);
- the target of the MRD is ErbB2. In one embodiment of the present invention, the target of the MRD is ErbB3. In one embodiment of the present invention, the target of the MRD is tumor-associated surface antigen epithelial cell adhesion molecule (Ep-CAM).
- Ep-CAM tumor-associated surface antigen epithelial cell adhesion molecule
- the target of the MRD is VEGF.
- the peptide sequence of the VEGF targeting MRD is VEPNCDIHVMWEWECFERL (SEQ ID. NO.: 13).
- the target of the MRD is an insulin- like growth factor-I receptor.
- the peptide sequence of the insulin-like growth factor-I receptor targeting MRD is SFYSCLESLVNGPAEKSRGQWDGCRKK (SEQ ID NO: 14).
- Other illustrative IGF-IR targeting MRDs include, for example, a peptide with the TOmIUIaNFYQCIX 1 X 2 LX 3 X 4 X 5 PAEKSRGQWQECRTGG (SEQ ID NO:58), wherein X 1 is E or D ; X 2 is any amino acid; X 3 is any amino acid; X 4 is any amino acid and X 5 is any amino acid.
- Illustrative peptides that contain the formula include:
- NFYQCIEHLSGSPAEKSRGQWQECRTG SEQ ID NO: 42
- NFYQCIEMLSLPPAEKSRGQWQECRTG SEQ ID NO: 45
- the target of the MRD is a tumor antigen.
- the target of the MRD is an epidermal growth factor receptor (EGFR). In one embodiment of the present invention, the target of the MRD is an angiogenic factor. In one embodiment of the present invention, the target of the MRD is an angiogenic receptor.
- EGFR epidermal growth factor receptor
- the MRD is a vascular homing peptide.
- the peptide sequence of the vascular homing peptide is ACDCRGDCFCG (SEQ ID. NO: 15).
- the target of the MRD is a nerve growth factor.
- the antibody binds to a cell surface antigen.
- the antibody or MRD binds to EGFR, ErbB2, ErbB3, ErbB4, CD20, insulin-like growth factor-I receptor, or prostate specific membrane antigen.
- the peptide sequence of the EGFR targeting MRD is VDNKFNKELEKAYNEIRNLPNLNGWQMTAFIASLVDDPSQSANLLAEAKKLNDAQA PK (SEQ ID NO: 16).
- the peptide sequence of the EGFR targeting MRD is VDNKFNKEMWIAWEEIRNLPNLNGWQMTAFIASLVDDPSQSANLLAEAKKLNDAQ APK (SEQ ID NO: 17).
- the peptide sequence of ErbB2 targeting MRD is
- the antibody binds to an angiogenic factor.
- the antibody binds to an angiogenic receptor.
- the present invention also relates to an isolated polynucleotide comprising a nucleotide sequence of the antibody.
- a vector comprises the polynucleotide.
- the polynucleotide is operatively linked with a regulatory sequence that controls expression on the polynucleotide.
- a host cell comprises the polynucleotide or progeny.
- the present invention also relates to a method of treating a disease a subject in need thereof is provided, the method comprising administering an antibody comprising an MRD.
- the disease is cancer.
- undesired angiogenesis in inhibited.
- angiogenesis is modulated.
- tumor growth is inhibited.
- a method of treatment comprising administering an additional therapeutic agent along with an antibody comprising an MRD is described.
- the present invention also relates to a method of making a full length antibody comprising a MRD is described.
- the MRD is derived from a phage display library.
- the MRD is derived from natural ligands.
- the antibody is chimeric or humanized.
- FIG. 1 shows the schematic representation of different designs of tetravalent IgG- like BsAbs.
- FIG. 2A shows a typical peptibody as C-terminal fusion with Fc.
- FIG. 2B shows an antibody with a C-terminal MRD fusion with the light chain of the antibody.
- FIG. 2C shows an antibody with an N-terminal MRD fusion with the light chain of the antibody.
- FIG. 2D shows an antibody with unique MRD peptides fused to each terminus of the antibody.
- FIG. 3 depicts the results of an ELISA in which integrin and Ang2 were bound by an anti-integrin antibody fused to a ang-2 targeting MRD.
- FIG. 4 depicts the results of an ELISA in which integrin and Ang2 were bound by an anti-integrin antibody fused to a ang-2 targeting MRD.
- FIG. 5 depicts the results of an ELISA in which an anti-ErbB2 antibody was fused to an MRD which targeted Ang2.
- FIG. 6 depicts the results of an ELISA in which an Ang2 targeting MRD was fused to a hepatocyte growth factor receptor binding antibody.
- FIG. 7 depicts the results of an ELISA in which an integrin targeting MRD was fused to an ErbB2 binding antibody.
- FIG. 8 depicts the results of an ELISA in which an integrin targeting MRD was fused to an hepatocyte growth factor receptor binding antibody.
- FIG. 9 depicts the results of an ELISA in which an insulin-like growth factor-I receptor targeting MRD was fused to an ErbB2 binding antibody.
- FIG. 10 depicts the results of an ELISA in which a VEGF-targeting MRD was fused to an ErbB2 binding antibody.
- FIG. 11 depicts the results of an ELISA in which an integrin targeting MRD was fused to a catalytic antibody.
- FIG. 12 depicts the results of an ELISA in which an Ang-2-targeting MRD was fused to a catalytic antibody.
- FIG. 13 depicts the results of an ELISA in which an integrin and Ang-2 targeting MRD was fused to an ErbB2 binding antibody.
- FIG. 14 depicts the results of an ELISA in which an integrin targeting MRD was fused to an ErbB2-binding antibody.
- FIG. 15 depicts the results of an ELISA in which an integrin, Ang-2, or insulin- like growth factor-I receptor-targeting MRD was fused to an ErbB2 or hepatocyte growth factor receptor-binding antibody with a short linker peptide.
- FIG. 16 depicts the results of an ELISA in which an integrin, Ang-2, or insulin- like growth factor-I receptor-targeting MRD was fused to an ErbB2 or hepatocyte growth factor receptor-binding antibody with a long linker peptide.
- antibody used herein to refer to intact immunoglobulin molecules and includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies.
- An intact antibody comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
- Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
- the heavy chain constant region is comprised of three domains, CH 1 , CH 2 and CH 3 .
- Each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region.
- the light chain constant region is comprised of one domain, C L .
- V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each V H and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FRl , CDRl, FR2, CDR2, FR3, CDR3, FR4.
- the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
- a “dual-specific antibody” is used herein to refer to an immunoglobulin molecule which contain dual-variable-domain immunoglobins, where the dual-variable-domain can be engineered from any two monoclonal antibodies.
- an "antibody combining site” is that structural portion of an antibody molecule comprised of a heavy and light chain variable and hypervariable regions that specifically binds (immunoreacts with) an antigen.
- the term "immunoreact” in its various forms means specific binding between an antigenic determinant-containing molecule and a molecule containing an antibody combining site such as a whole antibody molecule or a portion thereof.
- polypeptide refers to a peptide or polypeptide which comprises less than a complete, intact antibody.
- naturally occurring when used in connection with biological materials such as a nucleic acid molecules, polypeptides, host cells, and the like refers to those which are found in nature and not modified by a human being.
- Monoclonal antibody refers to a population of antibody molecules that contain only one species of antibody combining site capable of immunoreacting with a particular epitope.
- a monoclonal antibody thus typically displays a single binding affinity for any epitope with which it immunoreacts.
- a monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.
- a “modular recognition domain” (MRD) or "target binding peptide” is a molecule, such as a protein, glycoprotein and the like, that can specifically (non-randomly) bind to a target molecule.
- the amino acid sequence of a MRD site can tolerate some degree of variability and still retain a degree of capacity to bind the target molecule. Furthermore, changes in the sequence can result in changes in the binding specificity and in the binding constant between a preselected target molecule and the binding site.
- Cell surface receptor refers to molecules and complexes of molecules capable of receiving a signal and the transmission of such a signal across the plasma membrane of a cell.
- An example of a cell surface receptor of the present invention is an activated integrin receptor, for example, an activated ⁇ v ⁇ 3 integrin receptor on a metastatic cell.
- target binding site or "target site” is any known, or yet to be described, amino acid sequence having the ability to selectively bind a preselected agent.
- exemplary reference target sites are derived from the RGD-dependent integrin ligands, namely fibronectin, fibrinogen, vitronectin, von Willebrand factor and the like, from cellular receptors such as VEGF, ErbB2, vascular homing peptide or angiogenic cytokines, from protein hormones receptors such as insulin-like growth factor-I receptor, epidermal growth factor receptor and the like, and from tumor antigens.
- protein is defined as a biological polymer comprising units derived from amino acids linked via peptide bonds; a protein can be composed of two or more chains.
- a "fusion polypeptide” is a polypeptide comprised of at least two polypeptides and optionally a linking sequence to operatively link the two polypeptides into one continuous polypeptide.
- the two polypeptides linked in a fusion polypeptide are typically derived from two independent sources, and therefore a fusion polypeptide comprises two linked polypeptides not normally found linked in nature.
- linker refers to a peptide located between the antibody and the MRD.
- Linkers can have from about 2 to 20 amino acids, usually 4 to 15 amino acids.
- Target cell refers to any cell in a subject (e.g., a human or animal) that can be targeted by the antibody comprising an MRD of the invention.
- the target cell can be a cell expressing or overexpressing the target binding site, such as activated integrin receptor.
- "Patient,” “subject,” “animal” or “mammal” are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Animals include all vertebrates, e.g., mammals and non-mammals, such as sheep, dogs, cows, chickens, amphibians, and reptiles.
- Treating includes the administration of the antibody comprising an MRD of the present invention to prevent or delay the onset of the symptoms, complications, or biochemical indicia of a disease, alleviating the symptoms or arresting or inhibiting further development of the disease, condition, or disorder.
- Treatment can be prophylactic (to prevent or delay the onset of the disease, or to prevent the manifestation of clinical or subclinical symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of the disease.
- Treatment can be with the antibody-MRD composition alone, or it can be used in combination with an additional therapeutic agent.
- compositions, carriers, diluents and reagents are used interchangeably and represent that the materials are capable of administration to or upon a human without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
- Modulate means adjustment or regulation of amplitude, frequency, degree, or activity.
- modulation may be positively modulated (e.g., an increase in frequency, degree, or activity) or negatively modulated (e.g., a decrease in frequency, degree, or activity).
- Cancer “tumor,” or “malignancy” are used as synonymous terms and refer to any of a number of diseases that are characterized by uncontrolled, abnormal proliferation of cells, the ability of affected cells to spread locally or through the bloodstream and lymphatic system to other parts of the body (metastasize) as well as any of a number of characteristic structural and/or molecular features.
- a "cancerous,” “tumor,” or “malignant cell” is understood as a cell having specific structural properties, lacking differentiation and being capable of invasion and metastasis. Examples of cancers are, breast, lung, brain, bone, liver, kidney, colon, head and neck, ovarian, hematopoietic (e.g., leukemia), and prostate cancer.
- Humanized antibody or “chimeric antibody” includes antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
- the present invention describes an approach based on the adaptation of target binding peptides or modular recognition domains (MRDs) as fusions to catalytic or non- catalytic antibodies that provide for effective targeting of tumor cells or soluble molecules while leaving the prodrug activation capability of the catalytic antibody intact.
- MRDs can also extend the binding capacity of non-catalytic antibodies providing for an effective approach to extend the binding functionality of antibodies, particularly for therapeutic purposes.
- One aspect of the present invention relates to development of a full-length antibody comprising a modular recognition domain (MRD).
- MRD modular recognition domain
- the interaction between a protein ligand and its target receptor site often takes place at a relatively large interface. However, only a few key residues at the interface contribute to most of the binding. Thus, molecules of peptide length (generally 2 to 60 amino acids) can bind to the receptor protein of a given large protein ligand. It is contemplated that MRDs of the present invention contain a peptide sequence that bind to target sites of interests and are about 2 to 60 amino acids.
- integrins such as ⁇ v ⁇ 3 and ⁇ v ⁇ 5 as tumor-associated markers has been well documented.
- a recent study of 25 permanent human cell lines established from advanced ovarian cancer demonstrated that all lines were positive for ⁇ v ⁇ 5 expression and many were positive for ⁇ v ⁇ 3 expression.
- integrin ⁇ v ⁇ 3 and ⁇ v ⁇ 5 antagonists are in clinical development. These include cyclic RGD peptides and synthetic small molecule RGD mimetics.
- Two antibody-based integrin antagonists are currently in clinical trials for the treatment of cancer. The first is Vitaxin, the humanized form of the murine anti-human ⁇ v ⁇ 3 antibody LM609. A dose-escalating phase I study in cancer patients demonstrated that it was safe for use in humans. Another antibody in clinical trials is CNT095, a fully human rnAb that recognizes ⁇ v integrins.
- CNT095 a fully human rnAb that recognizes ⁇ v integrins.
- a Phase I study of CNT095 in patients with a variety of solid tumors has shown that it is well tolerated.
- Cilengitide a peptide antagonist of ⁇ v ⁇ 3 and ⁇ v ⁇ 5
- An example of an integrin-binding MRD is an RGD tripeptide-containing binding site, and is exemplary of the general methods described herein.
- Ligands having the RGD motif as a minimum recognition domain are well known, a partial list of which includes, with the corresponding integrin target in parenthesis, fibronectin ( ⁇ 3 ⁇ l, ⁇ 5 ⁇ l, ⁇ v ⁇ l, ⁇ llb ⁇ 3, ⁇ v ⁇ 3, and ⁇ 3 ⁇ l) fibrinogen ( ⁇ M ⁇ 2 and ⁇ llb ⁇ l) von Willebrand factor ( ⁇ llb ⁇ 3 and ⁇ v ⁇ 3), and vitronectin ( ⁇ llb ⁇ 3, ⁇ v ⁇ 3 and ⁇ v ⁇ 5).
- RGD containing targeting MRDs useful in the present invention have amino acid residue sequences shown below:
- YCRGDCT (SEQ ID. NO.: 3) PCRGDCL (SEQ ID. NO.: 4) TCRGDCY (SEQ ID. NO.: 5) LCRGDCF (SEQ ID. NO.: 6)
- a MRD that mimics a non-RGD-dependent binding site on an integrin receptor and having the target binding specificity of a high affinity ligand that recognizes the selected integrin is also contemplated in the present invention.
- Angiogenesis is essential to many physiological and pathological processes.
- Ang2 has been shown to act as a proangiogenic molecule.
- Administration of Ang2-selective inhibitors is sufficient to suppress both tumor angiogenesis and corneal angiogenesis. Therefore, Ang2 inhibition alone or in combination with inhibition of other angiogenic factors such as VEGF may represent an effective antiangiogenic strategy for treating patients with solid tumors.
- MRDs useful in the present invention include those that bind to angiogenic receptors, angiogenic factors, and/or Ang-2. Examples of angiogenic cytokine targeting MRD sequences are listed below:
- nEF APWTn (SEQ ID NO: 22) where n is from about 0 to 50 amino acid residues AQQEECEFAPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEFAPWTCEHMLE (SEQ ID NO: 23) 2xConFA
- nELAPWTXn where n is from about 0 to 50 amino acid residues and X is any amino acid (SEQ ID NO: 25)
- n is from about 0 to 50 amino acid residues and X is any amino acid (SEQ ID NO: 28)
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 31) and wherein X is any amino acid
- Such peptides can be present in dimmers, trimers or other multimers either homologous or heterologous in nature.
- ConFA Another heterodimer is ConFA combined with ConFS to create ConFA-FS with the sequence: AQQEECEFAP WTCEHMGSGSATGGSGSTASSGSGSATHQEECEFSPWTCEHMLE (SEQ ID NO:34).
- the invention includes a peptide having the sequence:
- NFYQCIX I X 2 LX 3 X 4 X 5 PAEKSRGQWQECRTGG (SEQ ID NO:58), wherein Xi is E or D ; X 2 is any amino acid; X 3 is any amino acid; X 4 is any amino acid and X 5 is any amino acid.
- the invention also includes peptides having a core sequence selected from:
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 22);
- nELAPWTXn where n is from about 0 to 50 amino acid residues (SEQ ID NO: 25);
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 28);
- n is from about 0 to 50 amino acid residues (SEQ ID NO: 31); or
- n is from about 0 to 50 amino acid residues and X 3 X 1 and X 2 are any amino acid (SEQ ID NO:57).
- VEPNCDIHVMWEWECFERL Human Umbilical Vein Endothelial Cells
- Insulin-like growth factor-I receptor-specific MRDs can be used in the present invention.
- One example of an MRD sequence that targets the insulin-like growth factor-I receptor is SFYSCLESL VNGP AEKSRGQWDGCRKK (SEQ ID NO.: 14).
- Additional IGF-IR MRDs include the following:
- vascular homing MRDs are contemplated for use in the present invention.
- An MRD sequence that is a vascular homing peptide is ACDCRGDCFCG (SEQ ID NO.: 15).
- EGFR epidermal growth factor receptor
- CD20 tumor antigens
- ErbB2, ErbB3, ErbB4 insulin-like growth factor-I receptor
- NGR nerve growth factor
- hepatocyte growth factor receptor hepatocyte growth factor receptor
- Ep-CAM tumor-associated surface antigen epithelial cell adhesion molecule
- MRD sequences that bind to EGFR are listed below:
- VDNKFNKELEKAYNEIRNLPNLNGWQMTAFIASLVDDPSQSANLLAEAKKLNDAQA PK (SEQ ID. NO.: 16).
- VDNKFNKEMWIAWEEIRNLPNLNGWQMTAFIASLVDDPSQSANLLAEAKKLNDAQ APK SEQ ID. NO. 17.
- VDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLNDAQA PK (SEQ ID- NO.: 18).
- the sequence of the MRD can be determined several ways. MRD sequences can be derived from natural ligands or known sequences that bind to a specific target binding site can be used. Additionally, phage display technology has emerged as a powerful method in identifying peptides which bind to target receptors. In peptide phage display libraries, random peptide sequences can be displayed by fusion with coat proteins of filamentous phage. The methods for elucidating binding sites on polypeptides using phage display vectors has been previously described, in particular in WO 94/18221. The methods generally involve the use of a filamentous phage (phagemid) surface expression vector system for cloning and expressing polypeptides that bind to the pre-selected target site of interest.
- phagemid filamentous phage
- the methods of the present invention for preparing MRDs involve the use of phage display vectors for their particular advantage of providing a means to screen a very large population of expressed display proteins and thereby locate one or more specific clones that code for a desired target binding reactivity.
- the peptides may be prepared by any of the methods disclosed in the art.
- variants and derivatives of the MRDs are included within the scope of the present invention. Included within variants are insertional, deletional, and substitutional variants as well as variants that include MRDs presented here with additional amino acids at the N- and/or C-terminus, including from about 0 to 50, 0 to 40, 0 to 30, 0 to 20 amino acids and the like. It is understood that a particular MRD of the present invention may contain one, two, or all three types of variants. Insertional and substitutional variants may contain natural amino acids, unconventional amino acids, or both.
- Antibody 38C2 is an antibody-secreting hybridoma, and has been previously described in WO 97/21803. 38C2 contains an antibody combining site that catalyzes the aldol addition reaction between an aliphatic donor and an aldehyde acceptor. In a syngeneic mouse model of neuroblastoma, systemic administration of an etoposide prodrug and intra-tumor injection of Ab 38C2 inhibited tumor growth.
- A33 binding antibodies Human A33 antigen is a transmembrane glycoprotein of the Ig superfamily. The function of the human A33 antigen in normal and malignant colon tissue is not yet known, however, several properties of the A33 antigen suggest that it is a promising target for immunotherapy of colon cancer.
- These properties include (i) the highly restricted expression pattern of the A33 antigen, (ii) the expression of large amounts of the A33 antigen on colon cancer cells, (iii) the absence of secreted or shed A33 antigen, and (iv) the fact that upon binding of antibody A33 to the A33 antigen, antibody A33 is internalized and sequestered in vesicles, and (v) the targeting of antibody A33 to A33 antigen expressing colon cancer in preliminary clinical studies. Fusion of a MRD directed toward A33 to a catalytic or non-catalytic antibody would increase the therapeutic efficacy of A33 targeting antibodies.
- the present invention also contemplates the preparation of mono-, bi-, tri-, tetra-, and penta-specific antibodies. It is contemplated that the antibodies used in the present invention may be prepared by any method known in the art.
- the MRD may be attached to an antibody through the peptide's N-terminus or C- terminus.
- the MRD may be attached to the antibody at the C-terminal end of the heavy chain of the antibody, the N-terminal end of the heavy chain of the antibody, the C-terminal end of the light chain of the antibody, or the N-terminal end of the light chain of the antibody.
- the MRD may be attached to the antibody directly, or attached through an optional linker peptide, which can be between 2 to 20 peptides long.
- the linker peptide can contain a short linker peptide with the sequence GGGS (SEQ ID.
- the present invention also provides for two or more MRDs which are linked to any terminal end of the antibody. It is also contemplated that two or more MRDs can be directly attached or attached through a linker peptide to two or more terminal ends of the antibody. The multiple MRDs can target the same target binding site, or two or more different target binding sites. Additional peptide sequences may be added to enhance the in vivo stability of the MRD.
- the antibody-MRD fusion molecules can be encoded by a polynucleotice comprising a nucleotide sequence.
- a vector can contain the polynucleotide sequence.
- the polynucleotide sequence can also be linked with a regulatory sequence that controls expression of the polynucleotide in a host cell.
- a host cell, or its progeny, can contain the polynucleotide encoding the antibody-MRD fusion molecule.
- compositions of the present invention contemplates therapeutic compositions useful for practicing the therapeutic methods described herein.
- Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with at least one species of antibody comprising an MRD as described herein, dissolved or dispersed therein as an active ingredient.
- the therapeutic composition is not immunogenic when administered to a human patient for therapeutic purposes.
- compositions that contains active ingredients dissolved or dispersed therein are well understood in the art.
- compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or nonaqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
- the preparation can also be emulsified.
- an antibody - MRD containing composition can take the form of solutions, suspensions, tablets, capsules, sustained release formulations or powders, or other compositional forms.
- the active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
- Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
- the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
- the therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylarnine, 2- ethylamino ethanol, histidine, procaine and the like.
- Physiologically tolerable carriers are well known in the art.
- Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
- aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol, and other solutes.
- Liquid compositions can also contain liquid phases in addition to and to the exclusion of water.
- Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
- a therapeutic composition contains an antibody comprising a MRD of the present invention, typically in an amount of at least 0.1 weight percent of antibody per weight of total therapeutic composition.
- a weight percent is a ratio by weight of antibody to total composition.
- 0.1 weight percent is 0.1 grams of antibody-MRD per 100 grams of total composition.
- An antibody-containing therapeutic composition typically contains about 10 microgram (ug) per milliliter (ml) to about 100 milligrams (mg) per ml of antibody as active ingredient per volume of composition, and more preferably contains about 1 mg/ml to about 10 mg/ml (i.e., about 0.1 to 1 weight percent).
- a therapeutic composition in another embodiment contains a polypeptide of the present invention, typically in an amount of at least 0.1 weight percent of polypeptide per weight of total therapeutic composition.
- a weight percent is a ratio by weight of polypeptide to total composition.
- 0.1 weight percent is 0.1 grams of polypeptide per 100 grams of total composition.
- an polypeptide-containing therapeutic composition typically contains about 10 microgram (ug) per milliliter (ml) to about 100 milligrams (mg) per ml of polypeptide as active ingredient per volume of composition, and more preferably contains about 1 mg/ml to about 10 mg/ml (i.e., about 0.1 to 1 weight percent).
- the presently described antibody-MRD molecules are particularly well suited for in vivo use as a therapeutic reagent.
- the method comprises administering to the patient a therapeutically effective amount of a physiologically tolerable composition containing an antibody comprising a MRD of the invention.
- the dosage ranges for the administration of the antibody comprising a MRD of the invention are those large enough to produce the desired effect in which the disease symptoms mediated by the target molecule are ameliorated.
- the dosage should not be so large as to cause adverse side effects, such as hyperviscosity syndromes, pulmonary edema, congestive heart failure, and the like.
- the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art.
- the dosage can be adjusted by the individual physician in the event of any complication.
- a therapeutically effective amount of an antibody comprising a MRD of this invention is typically an amount of antibody such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.1 microgram (ug) per milliliter (ml) to about 100 ug/ml, preferably from about 1 ug/ml to about 5 ug/ml, and usually about 5 ug/ml.
- the dosage can vary from about 0.1 mg/kg to about 300 mg/kg, preferably from about 0.2 mg/kg to about 200 mg/kg, most preferably from about 0.5 mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or several days.
- the antibody comprising a MRD of the invention can be administered parenterally by injection or by gradual infusion over time.
- the target molecule can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains the target molecule.
- antibodies comprising a MRD of the invention can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, and can be delivered by peristaltic means.
- the therapeutic compositions containing a human monoclonal antibody or a polypeptide of this invention are conventionally administered intravenously, as by injection of a unit dose, for example.
- unit dose when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.
- compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount.
- quantity to be administered depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual.
- suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for in vivo therapies are contemplated.
- Novel antibody-MRD fusion molecules were prepared by fusion of an integrin ⁇ v ⁇ 3 -targeting peptides to catalytic antibody 38C2. Fusions at the N-termini and C-termini of the light chain and the C-termini of the heavy chain were most effective. Using flow cytometry, the antibody conjugates were shown to bind efficiently to integrin ⁇ v ⁇ 3- expressing human breast cancer cells. The antibody conjugates also retained the retr ⁇ -aldol activity of their parental catalytic antibody 38C2, as measured by methodol and doxorubicin prodrug activation. This demonstrates that cell targeting and catalytic antibody capability can be efficiently combined for selective chemotherapy.
- Angiogenic cytokine targeting antibody - MRD fusion molecules were constructed.
- the antibody used was 38C2, which was fused with a MRD containing the 2xCon4 peptide
- Ang-2 MRD peptide (AQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE (SEQ ID. NO.: 10)).
- the MRD peptide was fused to either the N- or C-terminus of the light chain and the C-terminus of the heavy chain. Similar results were found with the other Ang- 2 MRD peptides. Additional Ang-2 MRD peptides include:
- n is from about 0 to 50 amino acid residues (SEQ ID NO:22)
- nELAPWTXn where n is from about 0 to 50 amino acid residues (SEQ ID NO:25)
- n is from about 0 to 50 amino acid residues (SEQ ID NO:28)
- n is from about 0 to 50 amino acid residues (SEQ ID NO:31)
- Such peptides can be present in dimmers, trimers or other multimers either homologous or heterologous in nature.
- ConFA ConFA combined with ConFS to create ConFA-FS with the sequence:
- 2xCon4 (AQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE (SEQ ID. NO.: 10)) was studied as an N-terminal fusion to the Kappa chain of the antibody (2xCon4-JC7U) and as a C-terminal fusion (JC7U-2xCon4). Both fusions maintained integrin and Ang2 binding.
- both antibody constructs (2xCon4-JC7U and JC7U-2xCon4) specifically bound to recombinant Ang2 as demonstrated by ELISA studies. Binding to Ang2, however, is significantly higher with JC7U-2xCon4, which has the 2xCon4 (SEQ ID. NO.: 10) fusion at the C-terminus of the light chain of the antibody.
- the right panel of Figure 3 depicts the binding of Ang2-JC7U and JC7U-Ang2 to integrin ⁇ v ⁇ 3. The results show that fusion of 2xCon4 (SEQ ID. NO.: 10) to either the N- or the C- light chain terminus does not affect mAb JC7U binding to integrin ⁇ v ⁇ 3.
- Figure 4 depicts another ELISA study using the same antibody-MRD fusion constructs.
- Herceptin - MRD fusion constructs Another example of MRD fusions to a non-catalytic antibody are Herceptin - MRD fusion constructs.
- the Herceptin-MRD fusions are multifunctional, both small- molecule ⁇ v integrin antagonists and the chemically programmed integrin-targeting antibody show remarkable efficacy in preventing the breast cancer metastasis by interfering with ⁇ v- mediated cell adhesion and proliferation.
- MRD fusions containing Herceptin-2xCon4 (which targets ErbB2 and ang2) and Herceptin- Vl 14 (which targets ErbB2 and VEGF targeting) and Herceptin-RGD-4C-2xCon4 (which targets ErbB2, ang2, and integrin targeting) are effective.
- Herceptin-2xCon4 which targets ErbB2 and ang2
- Herceptin- Vl 14 which targets ErbB2 and VEGF targeting
- Herceptin-RGD-4C-2xCon4 which targets ErbB
- An antibody containing an MRD that targets VEGF was constructed.
- a MRD which targets vl 14 (SEQ ID. NO. 13) was fused at the N-terminus of the kappa chain of 38C2 and Herceptin using the long linker sequence (SEQ ID. NO. 2).
- Expression and testing of the resulting antibody-MRD fusion constructs demonstrated strong VEGF binding.
- Rm2-2-218 GTGGAGTGCAGGGCGCCG VECRAP SEQ ID NO: 50, Rm2-2-316 GCTGAGTGCAGGGCTGGG AECRAG SEQ ID NO: 52, Rm2-2-319 CAGGAGTGCAGGACGGGG QECRTG SEQ ID NO: 54,
- An antibody was constructed which contains an MRD that targets Ang-2 (L 17) fused to the light chain of an antibody which binds to ErbB2. Either the short linker sequence, the long linker sequence, or the 4th loop in the light chain constant region was used as a linker.
- Figure 5 depicts the results of an ELISA using constructs containing an N- terminal fusion of Ang-2 targeting MRD with the ErbB2 antibody with the short linker peptide (GGGS (SEQ ID NO.: I)) (L17-sL-Her), a C-terminal fusion of Ang-2 targeting MRD with the ErbB2 antibody with the short linker peptide (Her-sL-L17), a C-terminal fusion of Ang-2 targeting MRD with the ErbB2 antibody with the 4th loop in the light chain constant region (Her-lo-L17), or an N-terminal fusion of Ang-2 targeting MRD with the ErbB2 antibody with the long linker peptide (SSGGGGSGGGGGGSSRSS (SEQ ID NO.: 19)) (L17-1L-Her).
- GGGS short linker peptide
- ErbB2 was bound with varying degrees by all of the constructs. However, Ang-2 was bound only by Her-sL-L17 and L17-1L-Her.
- Example 8 Hepatocyte Growth Factor Receptor Binding, Ang-2-Targeting Antibody-
- Fusion of an MRD which targets Ang-2 (L17) was made to either the N-terminus or C-terminus of the light chain of the Met antibody, which binds to hepatocyte growth factor receptor. Either the short linker sequence or the long linker sequence were used as a connector.
- Figure 6 depicts the results of an ELISA using constructs containing N-terminal fusion of Ang-2 targeting MRD with the Met antibody with the short linker peptide (GGGS (SEQ ID NO.: I)) (L17-sL-Met), N-terminal fusion of Ang-2 targeting MRD with the Met antibody with the long linker peptide (SSGGGGSGGGGGGSSRSS (SEQ ID NO.: 19)) (L 17- 1L-Met), and C-terminal fusion of Ang-2 targeting MRD with the Met antibody with the long linker peptide (Met-iL-L17).
- Expression and testing of the resulting antibody-MRD fusion constructs demonstrated strong Ang-2 binding when the long linker peptide was used. Fusion of the Ang-2 targeting MRD to the C-light chain terminus of the antibody resulted in slightly higher binding to Ang-2 then fusion of the Ang-2 targeting to the N-light chain terminus of the antibody.
- An antibody was constructed which contains an MRD that targets integrin ⁇ v ⁇ 3 (RGD4C) fused to the light chain of an antibody Herceptin which binds to ErbB2 (Her). Either the short linker sequence, the long linker sequence, or the 4th loop in the light chain constant region was used as a linker.
- Figure 7 depicts the results of an ELISA using constructs containing an N-terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the ErbB2 antibody with the short linker peptide (GGGS (SEQ ID NO.: I)) (RGD4C-sL-Her), a C- terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the ErbB2 antibody with the short linker peptide (Her-sL-RGD4C), a C-terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the ErbB2 antibody with the 4th loop in the light chain constant region (Her-lo-RGD4C), or an N-terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the ErbB2 antibody with the long linker peptide (SSGGGGSGGGGGGSSRSS (SEQ ID NO.: 19)) (RGD4C-1L-Her).
- ErbB2 was bound with varying degrees by all of the constructs.
- FIG. 8 depicts the results of an ELISA using constructs containing an N-terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the hepatocyte growth factor receptor antibody (RGD4C- 1L-Met), or a C-terminal fusion of integrin ⁇ v ⁇ 3 targeting MRD with the hepatocyte growth factor receptor antibody (Met-1L-RGD4C).
- RGD4C-1L-Met demonstrated strong integrin ⁇ v ⁇ 3 binding.
- Antibodies were constructed which contains an MRD that targets insulin-like growth factor-I receptor (RP) fused to the light chain of an antibody which binds to ErbB2 (Her). Either the short linker peptide, the long linker peptide, or the 4th loop in the light chain constant region was used as a linker. (Carter et al., Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9.
- Figure 9 depicts the results of an ELISA using constructs containing an N-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 antibody with the short (RP-sL-Her), a C-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 antibody and the short linker peptide (Her-sL-RP), a C-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 antibody with the 4th loop in the light chain constant region (Her-lo-RP), an N-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 antibody with the long linker peptide (RP-lL-Her), or a C-terminal fusion of insulin-like growth factor-I receptor targeting
- ErbB2 was bound with varying degrees by all of the constructs. Insulin-like growth factor-I receptor was bound by RP-lL-Her. Example 12. ErbB2 Binding. VEGF-Targeting Antibodv-MRD Molecules
- FIG. 10 depicts the results of an ELISA using a construct containing an N-terminal fusion of VEGF targeting MRD with the ErbB2-binding antibody with the medium linker peptide (Vl 14-mL-Her). Expression and testing of the resulting antibody-MRD fusion construct demonstrated strong VEGF and ErbB2 binding.
- FIG. 14 depicts the results of an ELISA using the construct. Both integrin and ErbB2 were bound by the construct.
- Antibody-MRD molecules were constructed which contain ErbB2 or hepatocyte growth factor receptor binding antibodies, and integrin ⁇ v ⁇ 3, Ang-2 or insulin-like growth factor-I receptor-targeting MRD regions were linked with the short linker peptide to the light chain of the antibody.
- Figure 15 depicts the results of an ELISA using constructs containing an N-terminal fusion of Ang-2 targeting MRD fused to the ErbB2 antibody (L17-sL-Her), an N-terminal fusion of integrin-targeting MRD with the ErbB2 antibody (RGD4C-sL-Her), an N-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 binding antibody (RP-sL-Her), a C-terminal fusion of Ang-2 targeting MRD with the hepatocyte growth factor receptor binding antibody (L17-sL-Met), a C-terminal fusion of Ang-2 targeting MRD with the ErbB2 binding antibody (Her-sL-L17), a C-terminal fusion of integrin targeting MRD with the ErbB2 binding antibody (Her-sL-RGD4C), or a C-terminal fusion of insulin-like growth factor-I receptor targeting MRD with the ErbB2 binding antibody (Her-sL-RP
- Antibody-MRD molecules were constructed which contain ErbB2 or hepatocyte growth factor receptor binding antibodies, and integrin ⁇ v ⁇ 3, Ang-2 or insulin-like growth factor-I receptor-targeting MRD regions linked with the long linker peptide to the light chain of the antibody.
- Figure 16 depicts the results of an ELISA using constructs containing an N- terminal fusion of Ang-2 targeting MRD fused to the ErbB2 antibody (L17-1L-Her), an N- terminal fusion of integrin-targeting MRD with the ErbB2 antibody (RGD4C-1L-Her), an N- terminal fusion of insulin-like growth factor-I receptor- targeting MRD with the ErbB2 binding antibody (RP-lL-Her), a C-terminal fusion of Ang-2 targeting MRD with the hepatocyte growth factor receptor binding antibody (L17-1L-Met), a C-terminal fusion of integrin targeting MRD with the hepatocyte growth factor receptor binding antibody (RGD4C-1L-Met), a C-terminal fusion of Ang-2 targeting MRD with the insulin-like growth factor-I receptor binding antibody (Her-lL-RP), a C-terminal fusion of Ang-2 targeting MRD with the the hepatocyte growth factor receptor binding antibody (Met-1L-L17), or
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
Abstract
Description
Claims
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08870383A EP2237797A4 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
KR1020107017256A KR101658247B1 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
BRPI0821906-0A BRPI0821906B1 (en) | 2008-01-03 | 2008-12-24 | Isolated full-length antibody, its use, polynucleotide, vector, and host cell |
US12/747,883 US20110189206A1 (en) | 2008-01-03 | 2008-12-24 | Antibody Targeting Through a Modular Recognition Domain |
MX2010007357A MX2010007357A (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain. |
AU2008346734A AU2008346734A1 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
CN202210664506.7A CN115043946A (en) | 2008-01-03 | 2008-12-24 | Antibody targeting via modular recognition domains |
EP14154498.1A EP2769991B1 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
EA201070822A EA021967B1 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
CA2711256A CA2711256C (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
NZ586701A NZ586701A (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
JP2010541504A JP5774851B2 (en) | 2008-01-03 | 2008-12-24 | Antibodies targeting through a modular recognition domain |
CN2008801275841A CN101965406A (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
IL206602A IL206602A0 (en) | 2008-01-03 | 2010-06-24 | Antibody targeting through a modular recognition domain |
ZA2010/04730A ZA201004730B (en) | 2008-01-03 | 2010-07-05 | Antibody targeting through a modular recognition domain |
US13/135,789 US8557243B2 (en) | 2008-01-03 | 2011-07-14 | EFGR antibodies comprising modular recognition domains |
US13/135,754 US8454960B2 (en) | 2008-01-03 | 2011-07-14 | Multispecific antibody targeting and multivalency through modular recognition domains |
US13/135,786 US8557242B2 (en) | 2008-01-03 | 2011-07-14 | ERBB2 antibodies comprising modular recognition domains |
US13/135,788 US8574577B2 (en) | 2008-01-03 | 2011-07-14 | VEGF antibodies comprising modular recognition domains |
US13/694,155 US20130195860A1 (en) | 2008-01-03 | 2012-11-01 | Antibody targeting through a modular recognition domain |
IL223647A IL223647A0 (en) | 2008-01-03 | 2012-12-16 | Antibody targeting through a modular recognition domain |
US13/815,632 US20130303733A1 (en) | 2008-01-03 | 2013-03-13 | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
US14/053,860 US20140127200A1 (en) | 2008-01-03 | 2013-10-15 | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
US14/963,722 US10030051B2 (en) | 2008-01-03 | 2015-12-09 | Antibody targeting through a modular recognition domain |
IL248905A IL248905A0 (en) | 2008-01-03 | 2016-11-10 | Antibody targeting through a modular recognition domain |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1881608P | 2008-01-03 | 2008-01-03 | |
US61/018,816 | 2008-01-03 | ||
US2276708P | 2008-01-22 | 2008-01-22 | |
US61/022,767 | 2008-01-22 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/747,883 Continuation-In-Part US20110189206A1 (en) | 2008-01-03 | 2008-12-24 | Antibody Targeting Through a Modular Recognition Domain |
PCT/US2008/088337 Continuation-In-Part WO2009088805A2 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
Related Child Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/747,883 A-371-Of-International US20110189206A1 (en) | 2008-01-03 | 2008-12-24 | Antibody Targeting Through a Modular Recognition Domain |
US12/747,883 Continuation-In-Part US20110189206A1 (en) | 2008-01-03 | 2008-12-24 | Antibody Targeting Through a Modular Recognition Domain |
PCT/US2008/088337 Continuation-In-Part WO2009088805A2 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
US13/135,789 Continuation-In-Part US8557243B2 (en) | 2008-01-03 | 2011-07-14 | EFGR antibodies comprising modular recognition domains |
US13/135,786 Continuation-In-Part US8557242B2 (en) | 2008-01-03 | 2011-07-14 | ERBB2 antibodies comprising modular recognition domains |
US13/135,788 Continuation-In-Part US8574577B2 (en) | 2008-01-03 | 2011-07-14 | VEGF antibodies comprising modular recognition domains |
US13/135,754 Continuation-In-Part US8454960B2 (en) | 2008-01-03 | 2011-07-14 | Multispecific antibody targeting and multivalency through modular recognition domains |
US13/694,155 Continuation US20130195860A1 (en) | 2008-01-03 | 2012-11-01 | Antibody targeting through a modular recognition domain |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009088805A2 true WO2009088805A2 (en) | 2009-07-16 |
WO2009088805A3 WO2009088805A3 (en) | 2009-12-30 |
Family
ID=40853673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/088337 WO2009088805A2 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
Country Status (18)
Country | Link |
---|---|
US (3) | US20110189206A1 (en) |
EP (2) | EP2237797A4 (en) |
JP (3) | JP5774851B2 (en) |
KR (1) | KR101658247B1 (en) |
CN (3) | CN108864285A (en) |
AU (1) | AU2008346734A1 (en) |
BR (1) | BRPI0821906B1 (en) |
CA (1) | CA2711256C (en) |
DK (1) | DK2769991T3 (en) |
EA (2) | EA201500156A3 (en) |
ES (1) | ES2689274T3 (en) |
GE (1) | GEP20156390B (en) |
IL (3) | IL206602A0 (en) |
MX (1) | MX2010007357A (en) |
NZ (1) | NZ586701A (en) |
SG (2) | SG189769A1 (en) |
WO (1) | WO2009088805A2 (en) |
ZA (1) | ZA201004730B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012007896A1 (en) | 2010-07-12 | 2012-01-19 | Covx Technologies Ireland, Ltd. | Multifunctional antibody conjugates |
WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
JP2013506435A (en) * | 2009-10-05 | 2013-02-28 | オプソニック セラピューティクス インコーポレイテッド | High-affinity adapter molecules for redirecting antibody specificity |
US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
US8513390B2 (en) | 2009-01-12 | 2013-08-20 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
US20140088019A1 (en) * | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
WO2014144722A3 (en) * | 2013-03-15 | 2014-11-06 | Amgen Inc. | Bispecific bivalent scfv-fc molecules |
EP2968541A4 (en) * | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US10000576B1 (en) | 2013-11-27 | 2018-06-19 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting HER2 |
US10030051B2 (en) | 2008-01-03 | 2018-07-24 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
US10421823B2 (en) | 2013-03-13 | 2019-09-24 | Amgen Inc. | Proteins specific for BAFF and B7RP1 and uses thereof |
US10421824B2 (en) | 2013-03-13 | 2019-09-24 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
US11208497B2 (en) | 2013-12-23 | 2021-12-28 | Zymeworks Inc. | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
US11478555B2 (en) | 2015-08-17 | 2022-10-25 | Seoul National University R&Db Foundation | Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof |
US11707486B2 (en) | 2017-01-05 | 2023-07-25 | Korea Research Institute Of Bioscience And Biotechnology | Natural killer cell expressing anti-cotinine chimeric antigen receptor |
US11930837B2 (en) | 2017-05-24 | 2024-03-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
US12006354B2 (en) | 2017-05-24 | 2024-06-11 | Novartis Ag | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer |
US12049496B2 (en) | 2017-01-20 | 2024-07-30 | Sanofi | Anti-TGF-beta antibodies and their use |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
WO2014189303A1 (en) * | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein |
KR101602870B1 (en) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | Method for Cell-penetrating and cytosol-localizing of intact immunoglobulin antibody, and use thereof |
KR101602876B1 (en) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | Method for inhibiting activated RAS using intact immunoglobulin antibody having Cell-penetrating ability and use thereof |
MX2018014554A (en) | 2016-05-27 | 2019-09-09 | Orum Therapeutics Inc | Cytosol-penetrating antibody and use thereof. |
WO2018102777A1 (en) * | 2016-12-01 | 2018-06-07 | University Of South Florida | Peptibodies, compositions thereof, and methods of treating atrial fibrillation |
TWI832600B (en) * | 2017-01-20 | 2024-02-11 | 美商健臻公司 | Bone-targeting antibodies |
WO2019013140A1 (en) | 2017-07-14 | 2019-01-17 | 三井化学株式会社 | Lithium boron fluorophosphate complex compound, composition containing lithium boron fluorophosphate, lithium boron fluorophosphate, additive for lithium secondary battery, non-aqueous electrolyte for battery, and lithium secondary battery |
EP3792358A4 (en) | 2018-05-10 | 2022-05-25 | Mirabiologics Inc. | Artificial protein containing antigen-binding region of antibody and being fused with physiologically active peptide |
KR20190143826A (en) | 2018-06-21 | 2019-12-31 | 오름테라퓨틱 주식회사 | Cell/tissue-specific cell-penetrating antibodies |
US20210340277A1 (en) * | 2018-10-11 | 2021-11-04 | The Scripps Research Institute | Antibody compounds with reactive arginine and related antibody drug conjugates |
JP7317343B2 (en) * | 2019-03-20 | 2023-07-31 | 公立大学法人大阪 | Preventive or therapeutic agent for breast cancer and agent for suppressing proliferation of breast cancer cells |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
DE68913658T3 (en) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Cloning of immunoglobulin sequences from the variable domains |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6027725A (en) | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
US6733752B1 (en) | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
WO1995024220A1 (en) | 1994-03-07 | 1995-09-14 | Medarex, Inc. | Bispecific molecules having clinical utilities |
US7063840B2 (en) | 1994-10-07 | 2006-06-20 | Regeneron Pharmaceuticals, Inc. | TIE-2 ligands, methods of making and uses thereof |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
CN102416176A (en) | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | Stabile isotonic lyophilized protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
CN103641885A (en) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | Protein purification by ion exchange chromatography |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
PL203114B1 (en) * | 1998-09-14 | 2009-08-31 | Regents Board Of | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
SK287357B6 (en) | 1999-02-12 | 2010-08-09 | The Scripps Research Institute | Use an alpha v beta 3 antagonist for the preparation of a pharmaceutical composition for treating a tumor cell and therapeutical composition and kit for treating a tumor or tumor metastases |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
DE60027564T3 (en) | 1999-06-07 | 2009-07-23 | Immunex Corp., Thousand Oaks | TEK ANTAGONISTS |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
JP4579471B2 (en) | 1999-06-25 | 2010-11-10 | ジェネンテック, インコーポレイテッド | Treatment of prostate cancer with anti-ErbB2 antibody |
ATE437655T1 (en) | 1999-06-25 | 2009-08-15 | Genentech Inc | HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
KR20090024308A (en) | 1999-08-27 | 2009-03-06 | 제넨테크, 인크. | Dosages for treatment with anti-erbb2 antibodies |
US6497909B1 (en) | 1999-09-09 | 2002-12-24 | General Mills, Inc. | Method of bleaching cereal grain |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
EP1272647B1 (en) * | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001081377A2 (en) | 2000-04-21 | 2001-11-01 | Amgen, Inc. | Integrin/adhesion antagonists |
JP2003534292A (en) | 2000-05-19 | 2003-11-18 | ジェネンテック・インコーポレーテッド | ERBB antagonist gene detection assays to increase the likelihood of effective response to cancer treatment |
KR20030068205A (en) * | 2001-01-09 | 2003-08-19 | 메르크 파텐트 게엠베하 | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
EP1361891A2 (en) * | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Artificial fusion proteins with reduced immunogenicity |
KR20090010127A (en) * | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | Expression technology for proteins containing a hybrid isotype antibody moiety |
IL145035A0 (en) | 2001-08-21 | 2002-06-30 | Yeda Res & Dev | Molecular linkers suitable for crystallization and structural analysis of molecules of interest and method of using same |
JP3798285B2 (en) * | 2001-10-02 | 2006-07-19 | 富士通株式会社 | Network topology collection device |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7736652B2 (en) * | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
US20070003514A1 (en) | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
IL149820A0 (en) * | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
US20070104710A1 (en) | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
ATE328906T1 (en) | 2002-06-28 | 2006-06-15 | Domantis Ltd | DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE |
US7749968B2 (en) * | 2002-08-05 | 2010-07-06 | The Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
US20040057969A1 (en) | 2002-09-20 | 2004-03-25 | Smith Mark L | Compositions containing stabilized hepatitis antigen and methods of their use |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US7803372B2 (en) | 2002-10-08 | 2010-09-28 | Immunomedics, Inc. | Antibody therapy |
SI1549344T1 (en) * | 2002-10-10 | 2015-05-29 | Merck Patent Gmbh | Pharmaceutical compositions directed to erb-b1 receptors |
US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | Anti-cd19 antibodies |
GB0320878D0 (en) | 2003-09-05 | 2003-10-08 | Celltech R&D Ltd | A protein involved in carcinoma |
EP1667717A2 (en) | 2003-09-09 | 2006-06-14 | GPC Biotech AG | Therapeutic human anti-mhc class ii antibodies and their uses |
US20050136044A1 (en) * | 2003-12-04 | 2005-06-23 | Watkins Jeffry D. | Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
CA2550551C (en) | 2004-01-16 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US7247443B2 (en) * | 2004-03-17 | 2007-07-24 | University Of Hawaii | Sensor constructs and detection methods |
DK1735348T3 (en) * | 2004-03-19 | 2012-07-16 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
WO2006020706A2 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
AU2005289685B2 (en) | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
JP2008523083A (en) | 2004-12-08 | 2008-07-03 | イムノメディクス, インコーポレイテッド | Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer |
US7973140B2 (en) | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
SI1772465T1 (en) | 2005-01-05 | 2009-06-30 | F Star Biotech Forsch & Entw | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
KR20130089280A (en) | 2005-01-21 | 2013-08-09 | 제넨테크, 인크. | Fixed dosing of her antibodies |
CN101163501A (en) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | Bispecific binding agents for modulating biological activity |
CA2615122A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CA2618482C (en) | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
WO2007097812A2 (en) * | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
EP1790358A1 (en) | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Protein constructs designed for targeting and lysis of cells |
GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
CA2632417A1 (en) | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
WO2007066109A1 (en) | 2005-12-06 | 2007-06-14 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
CA2633211A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
CN105709237A (en) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | Multivalent immunoglobulin-based bioactive assemblies |
WO2007084692A2 (en) | 2006-01-20 | 2007-07-26 | Welson Pharmaceuticals, Inc. | Immunoconjugates for treatment of infectious diseases |
AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
JP2009525727A (en) | 2006-02-02 | 2009-07-16 | ザ ジェネラル ホスピタル コーポレイション | Engineered antibody-stress protein fusion |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
CN101675158A (en) * | 2006-02-24 | 2010-03-17 | 阿里乌斯研究公司 | Cancerous desease modifying antibodies |
WO2008036449A2 (en) | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
CN101522717A (en) | 2006-08-04 | 2009-09-02 | 阿斯利康(瑞典)有限公司 | Antibodies to erbb2 |
EP2083017A4 (en) | 2006-09-14 | 2011-01-12 | Med & Biological Lab Co Ltd | Antibody having enhanced adcc activity and method for production thereof |
CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
WO2008070042A2 (en) | 2006-12-04 | 2008-06-12 | Medimmune, Inc. | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
CA2916671C (en) | 2007-01-17 | 2018-01-09 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
BRPI0807344A2 (en) | 2007-02-02 | 2014-05-20 | Baylor Res Inst | MULTI-VARIABLE ANTIGENS COMPLEXED WITH HUMANIZED MONOCLONAL STEERING ANTIBODY |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
BRPI0808418A2 (en) | 2007-03-02 | 2014-07-22 | Genentech Inc | PREDICTION OF RESPONSE TO A HER INHIBITOR |
JP2010521526A (en) | 2007-03-23 | 2010-06-24 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | Multivalent heterobifunctional polymer and method of use thereof |
EP2160200B1 (en) | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US20090148905A1 (en) | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US20140127200A1 (en) | 2008-01-03 | 2014-05-08 | The Scripps Research Institute | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
EP2247305A4 (en) | 2008-01-28 | 2012-11-14 | Medimmune Ltd | Stabilized angiopoietin-2 antibodies and uses thereof |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
WO2009142460A2 (en) | 2008-05-23 | 2009-11-26 | Samsung Electronics Co., Ltd. | Antibody-peptide fused synergibody |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
EP2315775A2 (en) | 2008-07-21 | 2011-05-04 | Compugen Ltd. | Angiopoietin derived peptides |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
AU2009324354B2 (en) | 2008-12-10 | 2016-04-14 | Ablynx Nv | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
WO2010108153A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
KR101688522B1 (en) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | Angiopoietin-2 specific antibodies and uses thereof |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
ES2704038T3 (en) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Multivalent and monovalent multispecific complexes and their uses |
BR112015023752B1 (en) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX |
-
2008
- 2008-12-24 NZ NZ586701A patent/NZ586701A/en unknown
- 2008-12-24 WO PCT/US2008/088337 patent/WO2009088805A2/en active Application Filing
- 2008-12-24 CA CA2711256A patent/CA2711256C/en active Active
- 2008-12-24 ES ES14154498.1T patent/ES2689274T3/en active Active
- 2008-12-24 MX MX2010007357A patent/MX2010007357A/en not_active Application Discontinuation
- 2008-12-24 JP JP2010541504A patent/JP5774851B2/en active Active
- 2008-12-24 US US12/747,883 patent/US20110189206A1/en not_active Abandoned
- 2008-12-24 SG SG2013026802A patent/SG189769A1/en unknown
- 2008-12-24 DK DK14154498.1T patent/DK2769991T3/en active
- 2008-12-24 AU AU2008346734A patent/AU2008346734A1/en not_active Abandoned
- 2008-12-24 SG SG10201605629VA patent/SG10201605629VA/en unknown
- 2008-12-24 EP EP08870383A patent/EP2237797A4/en not_active Withdrawn
- 2008-12-24 BR BRPI0821906-0A patent/BRPI0821906B1/en active IP Right Grant
- 2008-12-24 EA EA201500156A patent/EA201500156A3/en unknown
- 2008-12-24 CN CN201810794874.7A patent/CN108864285A/en active Pending
- 2008-12-24 EP EP14154498.1A patent/EP2769991B1/en active Active
- 2008-12-24 KR KR1020107017256A patent/KR101658247B1/en active IP Right Grant
- 2008-12-24 GE GEAP200811904A patent/GEP20156390B/en unknown
- 2008-12-24 CN CN2008801275841A patent/CN101965406A/en active Pending
- 2008-12-24 CN CN202210664506.7A patent/CN115043946A/en active Pending
- 2008-12-24 EA EA201070822A patent/EA021967B1/en not_active IP Right Cessation
-
2010
- 2010-06-24 IL IL206602A patent/IL206602A0/en unknown
- 2010-07-05 ZA ZA2010/04730A patent/ZA201004730B/en unknown
-
2012
- 2012-11-01 US US13/694,155 patent/US20130195860A1/en not_active Abandoned
- 2012-12-16 IL IL223647A patent/IL223647A0/en unknown
-
2015
- 2015-07-02 JP JP2015133213A patent/JP2015227345A/en active Pending
- 2015-12-09 US US14/963,722 patent/US10030051B2/en active Active
-
2016
- 2016-11-10 IL IL248905A patent/IL248905A0/en active IP Right Grant
-
2017
- 2017-09-29 JP JP2017190339A patent/JP2018015002A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP2237797A4 * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10030051B2 (en) | 2008-01-03 | 2018-07-24 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US10118961B2 (en) | 2009-01-12 | 2018-11-06 | Cytomx Therapeutics, Inc. | Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV |
US10059762B2 (en) | 2009-01-12 | 2018-08-28 | Cytomx Therapeutics, Inc. | Anti-EGFR activatable antibodies |
US10875913B2 (en) | 2009-01-12 | 2020-12-29 | Cytomx Therapeutics, Inc. | Methods of treatment using activatable anti-EGFR antibodies |
US9453078B2 (en) | 2009-01-12 | 2016-09-27 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
US8563269B2 (en) | 2009-01-12 | 2013-10-22 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
US8513390B2 (en) | 2009-01-12 | 2013-08-20 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
US10513549B2 (en) | 2009-02-23 | 2019-12-24 | Cytomx Therapeutics, Inc. | Cleavage-activatable interferon-alpha proprotein |
US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
US9644016B2 (en) | 2009-02-23 | 2017-05-09 | Cytomx Therapeutics, Inc. | Soluble notch receptor proproteins and methods of use thereof |
JP2013506435A (en) * | 2009-10-05 | 2013-02-28 | オプソニック セラピューティクス インコーポレイテッド | High-affinity adapter molecules for redirecting antibody specificity |
WO2012007896A1 (en) | 2010-07-12 | 2012-01-19 | Covx Technologies Ireland, Ltd. | Multifunctional antibody conjugates |
US10087222B2 (en) | 2010-07-15 | 2018-10-02 | Zyngenia, Inc. | Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides |
WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
US9676833B2 (en) | 2010-07-15 | 2017-06-13 | Zyngenia, Inc. | Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
US20140088019A1 (en) * | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
AU2017204032B2 (en) * | 2011-05-24 | 2019-10-03 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2012162561A3 (en) * | 2011-05-24 | 2013-05-02 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
AU2012258637B2 (en) * | 2011-05-24 | 2017-07-20 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CN106432506A (en) * | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | Multivalent and monovalent multispecific complexes and their uses |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CN103857699A (en) * | 2011-05-24 | 2014-06-11 | 泽恩格尼亚股份有限公司 | Multivalent and monovalent multispecific complexes and their uses |
US10526381B2 (en) | 2011-05-24 | 2020-01-07 | Zygenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CN103857699B (en) * | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | Multivalence and unit price polyspecific complex and application thereof |
US20150210765A1 (en) * | 2011-05-24 | 2015-07-30 | Zyngenia, Inc. | Multivalent and Monovalent Multispecific Complexes and Their Uses |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
EP3381943A1 (en) | 2012-07-25 | 2018-10-03 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US10421823B2 (en) | 2013-03-13 | 2019-09-24 | Amgen Inc. | Proteins specific for BAFF and B7RP1 and uses thereof |
US10421824B2 (en) | 2013-03-13 | 2019-09-24 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
US11492417B2 (en) | 2013-03-13 | 2022-11-08 | Amgen Inc. | Proteins specific for BAFF and B7RP1 and uses thereof |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US11753475B2 (en) | 2013-03-15 | 2023-09-12 | Amgen Inc. | Bispecific-Fc molecules |
WO2014144722A3 (en) * | 2013-03-15 | 2014-11-06 | Amgen Inc. | Bispecific bivalent scfv-fc molecules |
EP2968541A4 (en) * | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US11965036B2 (en) | 2013-11-27 | 2024-04-23 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
US11325981B2 (en) | 2013-11-27 | 2022-05-10 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting Her2 |
US10947319B2 (en) | 2013-11-27 | 2021-03-16 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting HER2 |
US10000576B1 (en) | 2013-11-27 | 2018-06-19 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting HER2 |
US11208497B2 (en) | 2013-12-23 | 2021-12-28 | Zymeworks Inc. | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
US11478555B2 (en) | 2015-08-17 | 2022-10-25 | Seoul National University R&Db Foundation | Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof |
US11136366B2 (en) | 2015-12-04 | 2021-10-05 | Novartis Ag | Methods of treating immune related disorders using antibody-cytokine engrafted compositions |
US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
US11707486B2 (en) | 2017-01-05 | 2023-07-25 | Korea Research Institute Of Bioscience And Biotechnology | Natural killer cell expressing anti-cotinine chimeric antigen receptor |
US12049496B2 (en) | 2017-01-20 | 2024-07-30 | Sanofi | Anti-TGF-beta antibodies and their use |
US11930837B2 (en) | 2017-05-24 | 2024-03-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
US12006354B2 (en) | 2017-05-24 | 2024-06-11 | Novartis Ag | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10030051B2 (en) | Antibody targeting through a modular recognition domain | |
US8574577B2 (en) | VEGF antibodies comprising modular recognition domains | |
US8454960B2 (en) | Multispecific antibody targeting and multivalency through modular recognition domains | |
US8557243B2 (en) | EFGR antibodies comprising modular recognition domains | |
US8557242B2 (en) | ERBB2 antibodies comprising modular recognition domains | |
JP7348249B2 (en) | VEGF-GRAB protein and drug conjugate and its uses | |
Groner et al. | Therapeutic antibodies | |
US20140127200A1 (en) | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains | |
US10280218B2 (en) | Antibodies binding to BMP4, and uses thereof | |
US20090060909A1 (en) | Antibody antagonists of ve-cadherin without adverse effects on vascular permeability | |
CN114685667B (en) | Mesothelin binding molecules and uses thereof | |
EA040917B1 (en) | DELIVERY OF ANTIBODIES AGAINST EGFR VIA A MODULAR RECOGNITION DOMAIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880127584.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08870383 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2711256 Country of ref document: CA Ref document number: 2010541504 Country of ref document: JP Ref document number: 12010501525 Country of ref document: PH Ref document number: MX/A/2010/007357 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4257/CHENP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008346734 Country of ref document: AU Ref document number: 586701 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008870383 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107017256 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201070822 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11904 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: 2008346734 Country of ref document: AU Date of ref document: 20081224 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12747883 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 223647 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: PI0821906 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100705 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 248905 Country of ref document: IL |